» Articles » PMID: 33064636

Is There a Role for Bismuth in Diarrhea Management?

Overview
Specialty General Medicine
Date 2020 Oct 16
PMID 33064636
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Diarrhea, an illness of both the developed and developing world, involves the burdensome characteristics of frequent bowel movements, loose stools, and abdominal discomfort. Diarrhea is a long-standing challenge in palliative care and can have a myriad of causes, making symptomatic treatment pertinent when illness evaluation is ongoing, when there is no definitive treatment approach, or when effective treatment cannot be attained. Symptomatic therapy is a common approach in palliative care settings. Bismuth is a suitable agent for symptomatic therapy and can be effectively employed for management of chronic diarrhea. The objective of this narrative review is to examine the role of bismuth in management of diarrheal symptoms. To explore this, PubMed (including Medline) and Embase were used to search the existing literature on bismuth and diarrhea published from 1980 to 2019. It was found that bismuth has potential utility for diarrheal relief in multiple settings, including microscopic colitis, traveler's diarrhea, gastrointestinal infection, cancer, and chemotherapy. It also has great potential for use in palliative care patients, due to its minimal side effects. Overall, the antisecretory, anti-inflammatory, and antibacterial properties of bismuth make it a suitable therapy for symptomatic treatment of diarrhea. The limited range of adverse side effects makes it an appealing option for patients with numerous comorbidities. Healthcare providers can explore bismuth as an adjunct therapy for diarrhea management in an array of conditions, especially in the palliative care setting.

Citing Articles

Diagnosis and Pharmacological Management of Microscopic Colitis in Geriatric Care.

Nielsen O, Pardi D Drugs Aging. 2024; 41(2):113-123.

PMID: 38231321 PMC: 10869377. DOI: 10.1007/s40266-023-01094-6.

References
1.
DuPont H, Flores Sanchez J, Ericsson C, Mendiola Gomez J, DuPont M, Cruz Luna A . Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med. 1990; 88(6A):15S-19S. DOI: 10.1016/0002-9343(90)90270-n. View

2.
Balducci L, Dolan D, Hoffe S . Palliative Care in Older Patients With Cancer. Cancer Control. 2015; 22(4):480-8. DOI: 10.1177/107327481502200414. View

3.
Cotter T, Pardi D . Current Approach to the Evaluation and Management of Microscopic Colitis. Curr Gastroenterol Rep. 2017; 19(2):8. DOI: 10.1007/s11894-017-0551-3. View

4.
Graham D, Estes M, Gentry L . Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology. 1983; 85(5):1017-22. View

5.
Jauregui-Amezaga A, Vermeire S, Geboes K . Contemporary methods for the diagnosis and treatment of microscopic colitis. Expert Rev Gastroenterol Hepatol. 2015; 10(1):47-61. DOI: 10.1586/17474124.2016.1096197. View